Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Glimepiride increases hypoglycemia risk in type 2 diabetes treatment
Última actualización 4 de julio de 2026
Key finding
Severe hypoglycemia occurred in 10 (0.8%) participants randomized to glargine.
This study evaluated the addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes. It found varying rates of hypoglycemia among the different treatments.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes. It found varying rates of hypoglycemia among the different treatments.
Clinical relevance
Understanding the risks of hypoglycemia associated with different diabetes medications is crucial for clinicians managing type 2 diabetes. This study highlights the need for careful consideration of treatment options to minimize adverse effects while effectively controlling blood sugar levels.
Keep in mind
The study did not assess long-term outcomes. Sample sizes for each intervention group may limit generalizability. Effectiveness of interventions remains unclear due to mixed results.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Elizabeth RS, Lawrence SP, Alokananda G, et al. Addition of glargine, glimepiride, liraglutide, or sitagliptin to metformin in type 2 diabetes: A randomized controlled trial. PLOS ONE. 2024;19(11):e0309907. doi:10.1371/journal.pone.0309907
Efectos Principales
Severe hypoglycemia occurred in 10 (0.8%) participants on glargine.
Severe hypoglycemia occurred in 16 (1.3%) participants on glimepiride.
Hypoglycemic symptoms were reported by 833 (68.3%) participants on glimepiride.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Glargine U100, Glimepiride, Liraglutide, and 1 more and Hypoglycemic symptoms, Severe hypoglycemia.
This study contributes evidence to
Primary intervention
Glargine U100
Primary outcomes
- Hypoglycemic symptoms
- Severe hypoglycemia
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
8
Evidence pairs
78
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Hypoglycemia
Evidencia relacionada
Relación de evidencia
Sulfonylureas and Hypoglycemia
Guardar evidencia
Relación de evidencia
DPP-4 Inhibitors and Hypoglycemia
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Glimepiride had the highest rate of hypoglycemic symptoms at 68.3%.
- Severe hypoglycemia rates were low for glargine (0.8%) and liraglutide (0.5%).
- Sitagliptin had a severe hypoglycemia rate of 0.3%.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients currently using metformin for diabetes management.
Tener en Cuenta
- Results may not be applicable to all populations with diabetes.
- The study focused on short-term outcomes rather than long-term effects.
- Variability in individual responses to medications may affect outcomes.
Entre Líneas
- The study did not assess long-term outcomes.
- Sample sizes for each intervention group may limit generalizability.
- Effectiveness of interventions remains unclear due to mixed results.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Glargine U100 and Hypoglycemia, Glargine U100 and Hypoglycemia.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Glargine U100 → Hypoglycemia
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Glargine U100 → Hypoglycemia
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Glargine U100 Evidence Hub
All studies on Glargine U100
1 studies
intervention_hubContributes to Glargine U100 evidence base.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
1 studies
outcome_hubMeasures Hypoglycemia as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Glargine U100 and Hypoglycemic symptoms
Intervention: Glargine U100Outcome: Hypoglycemic symptoms
1 results
All studies on Glargine U100 and Severe hypoglycemia
Intervention: Glargine U100Outcome: Severe hypoglycemia
1 results
All studies on Glargine U100
Intervention: Glargine U100
1 results
All studies measuring Hypoglycemic symptoms
Outcome: Hypoglycemic symptoms
1 results
All studies measuring Severe hypoglycemia
Outcome: Severe hypoglycemia
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Sulfonylureas affect hypoglycemia?
Strong Evidence
Sulfonylureas may improve Hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect hypoglycemia?
Moderate Evidence
DPP-4 Inhibitors may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Glargine U100 affect hypoglycemic symptoms?
Emerging Evidence
Glargine U100 appears to improve Hypoglycemic symptoms.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemic symptoms
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsSitagliptin improves kidney function in type 1 diabetesLiraglutide 3 mg pathway improves weight loss.Liraglutide improves glycaemic control in adults with T2D
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.